Genomic footprints of activated telomere maintenance mechanisms in cancer
Lina Sieverling, Chen Hong, Sandra D. Koser, Philip Ginsbach, Kortine Kleinheinz, Barbara Hutter, Delia M. Braun, Isidro Cortés‐Ciriano, Ruibin Xi, Rolf Kabbe, Peter J. Park, Roland Eils, Matthias Schlesner, Kadir C. Akdemir, Eva G. Álvarez, Adrian Baez‐Ortega, Paul C. Boutros, David D.l. Bowtell, Benedikt Brors, Kathleen H. Burns, Peter J. Campbell, Kin Chan, Ken Chen, Ana Dueso-Barroso, Andrew Dunford, Paul A. Edwards, Xavier Estivill, Dariush Etemadmoghadam, Lars Feuerbach, J. Lynn Fink, Milana Frenkel‐Morgenstern, Dale W. Garsed, Mark Gerstein, Dmitry A. Gordenin, David Haan, James E. Haber, Julian M. Hess, Marcin Imieliński, David Jones, Young Seok Ju, Marat D. Kazanov, Leszek J. Klimczak, Youngil Koh, Jan O. Korbel, Kiran Kumar, Eunjung Alice Lee, Jake June-Koo Lee, Yilong Li, Andy G. Lynch, Geoff Macintyre, Florian Markowetz, Iñigo Martincorena, Alexander Martinez‐Fundichely, Matthew Meyerson, Satoru Miyano, Hidewaki Nakagawa, Fábio C. P. Navarro, Stephan Ossowski, John V. Pearson, Montserrat Puiggròs, Karsten Rippe, Nicola D. Roberts, Steven A. Roberts, Bernardo Rodríguez–Martín, Steven E. Schumacher, Ralph Scully, Mark Shackleton, Nicholas D. Sidiropoulos, Chip Stewart, David Torrents, José M. C. Tubío, Izar Villasante, Nicola Waddell, Jeremiah A. Wala, Joachim Weischenfeldt, Lixing Yang, Xiaotong Yao, Sung-Soo Yoon, Jorge Zamora, Cheng‐Zhong Zhang, Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, Hiroyuki Aburatani, David J. Adams, Nishant Agrawal, Keun Soo Ahn, Sung-Min Ahn, Hiroshi Aikata, Rehan Akbani, Hikmat Al‐AhmadieNature Communications2020 · DOI
Cancers require telomere maintenance mechanisms for unlimited replicative potential, typically achieved through TERT activation or alternative telomere lengthening (ALT) associated with ATRX or DAXX loss. As part of the PCAWG Consortium, we analyzed whole-genome sequencing data from over 2,500 matched tumor-control samples across 36 tumor types to characterize the genomic footprints of these mechanisms. We found that while telomere content is increased in ATRX/DAXX-mutant tumors, it is moderately decreased in TERT-modified tumors. Furthermore, 25% of all tumors—and 80% of ATRX/DAXX-mutant tumors—exhibit somatic integrations of telomeric sequences into non-telomeric DNA. These ALT-driven tumors also display unique telomere variant repeat (TVR) distributions, including the enrichment of the singleton TVR TTCGGG. Our analysis provides a high-resolution map of the recurrent genomic alterations associated with telomere maintenance in cancer.
Introduction: Bypassing the Cellular Countdown
Normal cells possess a biological "countdown clock" in the form of telomeres—protective caps at chromosome ends that shorten with every division. To achieve the unlimited replicative potential necessary for malignancy, tumors must bypass senescence by actively maintaining these telomeres. Most cancers overactivate TERT (the gene for telomerase), while a minority utilize ALT, a recombination-based mechanism often triggered by mutations in ATRX or DAXX. This study seeks to identify the specific structural and sequence-based "scars" left by these divergent maintenance strategies across the human cancer landscape.
Methods: Mapping Repetitive Landscapes
Analyzing telomeric repeats is challenging because they cannot be uniquely aligned to a reference genome using standard tools. Utilizing data from the PCAWG Consortium, the research team employed specialized software called TelomereHunter to estimate telomere content by normalizing telomeric reads against sequencing coverage and GC content. The team also developed methods to detect "discordant" read pairs (telomeric sequences integrated into non-telomeric regions) and quantify Telomere Variant Repeats (TVRs). Finally, a random forest classifier was trained to distinguish between TERT-driven and ALT-driven tumors based on these genomic features.
Key Insights: The Genomic Scars of Immortality
The Content Paradox
A primary finding of the study is the "content paradox": counter-intuitively, tumors using TERT activation actually have lower telomere content than their healthy control cells. In contrast, ALT-driven (ATRX/DAXX-mutant) tumors show a significant increase in telomere content.
Telomere content comparison between ATRX/DAXX-mutant (ALT), TERT-modified, and other tumors.
Telomeric DNA does not always remain at chromosome ends. In 25% of all tumors, telomeric sequences are somatically integrated into the middle of chromosomes—a prevalence that rises to 80% in ALT-driven tumors. This mechanism is strongly associated with extreme genomic instability, including chromothripsis and breakage-fusion-bridge cycles. The abundance of extrachromosomal telomeric DNA in ALT cells may facilitate the repair of broken chromosomes, leading to these complex rearrangements.
A Pan-Cancer View of Telomere Dynamics
The distribution of telomere content varies significantly across different cancer types, reflecting the diverse ways different tissues manage their replicative limits.
Distribution of telomere content (log2 T/C ratio) across 36 different tumor types.
The researchers identified specific "singleton" variants—TTCGGG and TTTGGG—that are uniquely enriched or depleted in ALT tumors. These act as a highly specific genomic fingerprint, allowing the random forest classifier to distinguish between ALT-like and TERT-like tumors with an impressive AUC of 0.95.
Conclusion and Future Directions
While this study provides a comprehensive map of telomeric genomic footprints, questions remain regarding the biochemical drivers of specific TVR patterns. Future research using long-read sequencing may provide even clearer resolution of these telomeric "scars," potentially identifying new therapeutic vulnerabilities in cancers that rely on the ALT mechanism.
Summary updated
Abstract
Cancers require telomere maintenance mechanisms for unlimited replicative potential. They achieve this through TERT activation or alternative telomere lengthening associated with ATRX or DAXX loss. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, we dissect whole-genome sequencing data of over 2500 matched tumor-control samples from 36 different tumor types aggregated within the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium to characterize the genomic footprints of these mechanisms. While the telomere content of tumors with ATRX or DAXX mutations (ATRX/DAXX<sup>trunc</sup>) is increased, tumors with TERT modifications show a moderate decrease of telomere content. One quarter of all tumor samples contain somatic integrations of telomeric sequences into non-telomeric DNA. This fraction is increased to 80% prevalence in ATRX/DAXX<sup>trunc</sup> tumors, which carry an aberrant telomere variant repeat (TVR) distribution as another genomic marker. The latter feature includes enrichment or depletion of the previously undescribed singleton TVRs TTCGGG and TTTGGG, respectively. Our systematic analysis provides new insight into the recurrent genomic alterations associated with telomere maintenance mechanisms in cancer.
BibTeX
@inproceedings{sieverling2020genomic,
author = {Lina Sieverling and Chen Hong and Sandra D. Koser and Philip Ginsbach and Kortine Kleinheinz and Barbara Hutter and Delia M. Braun and Isidro Cortés‐Ciriano and Ruibin Xi and Rolf Kabbe and Peter J. Park and Roland Eils and Matthias Schlesner and Kadir C. Akdemir and Eva G. Álvarez and Adrian Baez‐Ortega and Paul C. Boutros and David D.L. Bowtell and Benedikt Brors and Kathleen H. Burns and Peter J. Campbell and Kin Chan and Ken Chen and Isidro Cortés‐Ciriano and Ana Dueso-Barroso and Andrew Dunford and Paul A. Edwards and Xavier Estivill and Dariush Etemadmoghadam and Lars Feuerbach and J. Lynn Fink and Milana Frenkel‐Morgenstern and Dale W. Garsed and Mark Gerstein and Dmitry A. Gordenin and David Haan and James E. Haber and Julian M. Hess and Barbara Hutter and Marcin Imieliński and David Jones and Young Seok Ju and Marat D. Kazanov and Leszek J. Klimczak and Youngil Koh and Jan O. Korbel and Kiran Kumar and Eunjung Alice Lee and Jake June-Koo Lee and Yilong Li and Andy G. Lynch and Geoff Macintyre and Florian Markowetz and Iñigo Martincorena and Alexander Martinez‐Fundichely and Matthew Meyerson and Satoru Miyano and Hidewaki Nakagawa and Fábio C. P. Navarro and Stephan Ossowski and Peter J. Park and John V. Pearson and Montserrat Puiggròs and Karsten Rippe and Nicola D. Roberts and Steven A. Roberts and Bernardo Rodríguez–Martín and Steven E. Schumacher and Ralph Scully and Mark Shackleton and Nicholas D. Sidiropoulos and Lina Sieverling and Chip Stewart and David Torrents and José M. C. Tubío and Izar Villasante and Nicola Waddell and Jeremiah A. Wala and Joachim Weischenfeldt and Lixing Yang and Xiaotong Yao and Sung-Soo Yoon and Jorge Zamora and Cheng‐Zhong Zhang and Benedikt Brors and Karsten Rippe and David Jones and Lars Feuerbach and Lauri A. Aaltonen and Federico Abascal and Adam Abeshouse and Hiroyuki Aburatani and David J. Adams and Nishant Agrawal and Keun Soo Ahn and Sung-Min Ahn and Hiroshi Aikata and Rehan Akbani and Kadir C. Akdemir and Hikmat Al‐Ahmadie},
title = {{Genomic footprints of activated telomere maintenance mechanisms in cancer}},
booktitle = {Nature Communications},
year = {2020},
doi = {10.1038/s41467-019-13824-9},
}